Trials / Completed
CompletedNCT04288232
Efficacy and Safety of Aflibercept as Mono-therapy in Treat and Extend Regimen for DME Patients in Taiwan
A Multicenter, Open-label, Prospective, Interventional Study to Assess the Efficacy and Safety of Aflibercept as Mono-therapy in Treat and Extend Regimen for DME Patients in Taiwan
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 45 (actual)
- Sponsor
- Taipei Veterans General Hospital, Taiwan · Other Government
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
Phase IIIb, multicenter, open-label, prospective, interventional study to assess the potential benefit of Aflibercept treatment administered IVT at a dosage of 2 mg with five monthly loading doses and then treat and extend over 48 weeks, with the primary endpoint as BCVA assessed at Week 52.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Aflibercept Injection [Eylea] | Intravitreal aflibercept Injection 2.0mg/0.05 ml |
Timeline
- Start date
- 2015-08-31
- Primary completion
- 2017-11-16
- Completion
- 2017-11-16
- First posted
- 2020-02-28
- Last updated
- 2020-02-28
Source: ClinicalTrials.gov record NCT04288232. Inclusion in this directory is not an endorsement.